Antibodies to amyloid beta

Patent metadata

Field	Value
Publication number	US-10662239-B2
Application number	US-201715793510-A
Country	US
Kind code	B2
Filing date	Oct 25, 2017
Priority date	Oct 15, 2012
Publication date	May 26, 2020
Grant date	May 26, 2020

Abstract

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

First claim

What is claimed is:

1. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40); wherein the antibody molecule comprises:
(i) a VH domain comprising the following HCDRs:
HCDR1 SEQ ID NO: 525,
HCDR2 SEQ ID NO: 526, and
HCDR3 SEQ ID NO: 527, and
(ii) a VL domain comprising the following LCDRs:
LCDR1 SEQ ID NO: 534,
LCDR2 SEQ ID NO: 535, and
LCDR3 SEQ ID NO: 536;
and wherein the VL domain has a methinonine at the amino acid position corresponding to position 80 of SEQ ID NO: 533.

2. The isolated antibody molecule of claim 1 , wherein the VH domain has a lysine at the amino acid position corresponding to position 43 of SEQ ID NO: 524.

3. The isolated antibody molecule of claim 1 , wherein the antibody molecule is a monoclonal antibody.

4. The isolated antibody molecule of claim 1 , wherein the antibody molecule is an scFv.

5. The isolated antibody molecule of claim 1 , wherein the antibody molecule is a Fab.

6. The isolated antibody molecule of claim 2 , wherein the antibody molecule is a monoclonal antibody.

7. The isolated antibody molecule of claim 2 , wherein the antibody molecule is an scFv.

8. The isolated antibody molecule of claim 2 , wherein the antibody molecule is a Fab.

9. A method of treating a human or animal subject in need thereof, the method comprising administering to the subject an antibody of claim 1 ; wherein the treatment at least reduces amyloidosis; treats Alzheimer's disease; improves cognition or reduces cognitive decline in an Alzheimer's disease or Down's syndrome patient; or treats macular degeneration.

10. The method of claim 9 , wherein the method is for reducing amyloidosis.

11. A method of treating a human or animal subject in need thereof, the method comprising administering to the subject an antibody of claim 2 ; wherein the treatment at least reduces amyloidosis; treats Alzheimer's disease; improves cognition or reduces cognitive decline in an Alzheimer's disease or Down's syndrome patient; or treats macular degeneration.

12. The method of claim 11 , wherein the method is for reducing amyloidosis.

Assignees

• Medimmune Ltd

Inventors

• Groves Maria
• Gustavsson Suzanne
• Höglund Kina
• Lloyd Chris
• Nickson Adrian
• Niva Camilla
• Simon Sylvia
• Lowne David
• Welsh Fraser
• Freskgärd Per-Ola

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title